Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (Nasdaq: VRCA) presented Phase 2 translational and clinical data for VP-315 at SITC (Nov 5–9, 2025). In Part 2, 82 subjects (92 tumors) received intratumoral VP-315; an exploratory immune analysis in 22 subjects (24 tumors) showed increased CD3+, CD4+, CD8+ T-cell and CD20+ B-cell densities and reduced immunosuppressive cells 12–14 weeks post-treatment.
Clinical outcomes reported: 97% objective response rate (post-hoc), 51% complete histologic clearance, 86% overall tumor-size reduction, and no treatment-related serious adverse events. Company reported End-of-Phase 2 FDA agreement and is preparing a pivotal Phase 3 program.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that the CHMP of the European Medicines Agency provided positive scientific advice supporting a Marketing Authorization Application (MAA) for YCANTH as a treatment for molluscum contagiosum.
The CHMP concluded that the primary and supportive secondary endpoints from previously completed Phase 3 studies in the U.S. and Japan are adequate and no additional Phase 3 studies are required. Verrica is initiating activities to support an MAA submission that could be filed as early as Q4 2026. The feedback covers adult and pediatric patients aged 2 years and older, and addresses study design, clinical safety data, and nonclinical/literature adequacy.
Verrica Pharmaceuticals (Nasdaq: VRCA) will present new Phase 2 data on VP-315, an oncolytic peptide for basal cell carcinoma (BCC), at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, November 5–9, 2025, in National Harbor, Maryland.
The company will deliver an oral presentation (Abstract 529) on November 6, 2025 during Concurrent Session 205b with a 12:46–12:54 p.m. ET presentation slot exploring local immune activation in the tumor microenvironment 12 weeks after VP-315. A companion poster with the same exploratory analysis will also be presented. The abstract will be posted on the SITC website on or about November 4, 2025 at 9:00 a.m. ET.
Verrica Pharmaceuticals (NASDAQ:VRCA) announced that its development partner, Torii Pharmaceutical, has received approval from Japan's Ministry of Health for YCANTH® (TO-208) to treat Molluscum Contagiosum. This approval triggers a $10 million milestone payment to Verrica, strengthening its balance sheet with non-dilutive capital.
The approval follows positive Phase 3 trial results in Japan, where YCANTH demonstrated statistically significant efficacy in achieving complete clearance of molluscum lesions compared to placebo. Verrica maintains global rights to YCANTH outside Japan and plans to initiate a global Phase 3 program for common warts treatment by the end of 2025.
Verrica Pharmaceuticals (NASDAQ:VRCA), a dermatology therapeutics company, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will present on Monday, September 8, 2025, at 9:30 am ET.
Investors can access the presentation through a live webcast available on Verrica's website, with a replay available for 90 days following the event.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported strong Q2 2025 financial results with total revenue of $12.7 million, including $4.5 million from YCANTH® sales and $8.0 million in milestone revenue from Torii Pharmaceutical. YCANTH showed impressive growth with 13,434 dispensed applicator units, representing a 32.8% sequential increase from Q1 2025.
The company achieved a net income of $0.2 million ($0.02 per share) compared to a net loss of $17.2 million in Q2 2024. Verrica completed a successful End of Phase 2 Meeting for VP-315 in basal cell carcinoma and is preparing for Phase 3 while exploring non-dilutive financing options. The company expects an additional $10 million milestone payment upon Japanese regulatory approval of YCANTH by year-end 2025.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, will host a conference call and webcast on August 12, 2025, at 4:30 p.m. ET to discuss its Q2 2025 financial results and provide a corporate update.
Participants can join via telephone using 1-800-267-6316 (domestic) or 1-203-518-9783 (international) with conference ID: VERRICA. The webcast will be available on the company's investor relations website and archived for 90 days.
Verrica Pharmaceuticals (NASDAQ:VRCA) reported significant growth in YCANTH® dispensed applicator units for Q2 2025, achieving 13,434 units, representing a 32.8% sequential increase from Q1 2025. This growth rate nearly doubled the previous quarter's 16.7% sequential growth.
The company received an $8 million milestone payment from Japanese partner Torii Pharmaceutical for initiating a global Phase 3 program in common warts. Additional potential includes a $10 million milestone payment upon YCANTH's approval in Japan for molluscum. The company also highlighted amendments to its Credit Agreement with OrbiMed and progress with VP-315 for basal cell carcinoma treatment.
Verrica Pharmaceuticals (Nasdaq: VRCA) has announced a significant amendment to its Collaboration and License Agreement with Torii Pharmaceutical for launching a global Phase 3 clinical trial of YCANTH® to treat common warts. The company will receive an $8 million milestone payment in July 2025 for initiating the study, and an additional $10 million milestone payment upon YCANTH's approval for molluscum contagiosum in Japan, expected by end of 2025.
The agreement includes Torii funding the first $40 million of out-of-pocket costs for the global study, covering approximately 90% of the current clinical budget. The study targets common warts, which affects 22 million patients in the United States alone, with no current FDA-approved prescription therapies. Verrica plans to dose the first patient in the U.S. Phase 3 trial in Q4 2025.
Under the amended agreement, Verrica maintains ownership of global rights to YCANTH for all indications outside Japan. The companies will split the Phase 3 program costs 50/50, with Verrica repaying its portion through offsets against future royalties and transfer price payments from Torii. Additionally, Verrica will initiate a manufacturing transfer to Torii for YCANTH applicators for the Japanese market.
Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, announced its participation in the upcoming Jefferies Global Healthcare Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will deliver a presentation on Wednesday, June 4, 2025, at 4:20 pm ET.
The event will be accessible via live webcast through the company's website and a dedicated link. A replay will be available for 90 days following the presentation in the Investors/Presentations & Events section of www.verrica.com.